Vogt-Koyanagi-Harada disease

Ashlin Joye, Eric Suhler

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Purpose of reviewHere, we provide an overview of Vogt-Koyanagi-Harada disease (VKH), including recent updates in our understanding of disease pathophysiology, classification and therapeutics.Recent findingsAdvancements in bioinformatics, metabolomics and genomics investigations continue to illuminate VKH pathogenesis, and may provide insight into future therapeutic options. Multimodal imaging is indispensable in the initial evaluation of VKH, and is becoming increasingly important in understanding disease pathogenesis, as well as monitoring therapeutic response. Enhanced VKH classification criteria, released in 2021, provide standardized guidelines and terminology for clinical and research purposes.SummaryModern research and imaging techniques continue to improve our understanding of VKH; more work is needed to further elucidate pathogenic mechanisms and establish optimal therapeutic recommendations.

Original languageEnglish (US)
Pages (from-to)574-582
Number of pages9
JournalCurrent opinion in ophthalmology
Issue number6
StatePublished - Nov 1 2021


  • Voyt-Koyanagi-Harada
  • autoimmune
  • classification criteria
  • multimodal imaging
  • uveitis

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Vogt-Koyanagi-Harada disease'. Together they form a unique fingerprint.

Cite this